 |
|
|
| |
RUBY-II: Efficacy and Safety of a Ribavirin-Free Ombitasvir/Paritaprevir/Ritonavir ± Dasabuvir Regimen in Patients
With Severe Renal Impairment or End-Stage Renal Disease and HCV Genotype 1a or 4 Infection
|
| |
| |
Reported by Jules Levin
AASLD 2016 Nov 11-15 Boston, MA
Edward Gane1, Ricard Sola2, Eric Cohen3, Stuart K Roberts4, Jacob George5, Richard Skoien6, Stephen Riordan7, Niloufar Mobashery3, Manal Abunimeh3, Daniel E Cohen3, Kosh Agarwal8
1Auckland City Hospital, Auckland, New Zealand; 2Hospital del Mar. IMIM, Universitat Autónoma de Barcelona, Barcelona, Spain; 3AbbVie Inc., North Chicago, Illinois, United States; 4Alfred Hospital, Melbourne, Australia; 5Westmead Hospital, Westmead Insti tute for Medical Research and University of Sydney, Westmead, Australia; 6Royal Brisbane and Women's Hospital, Brisbane, Australia; 7University of New South Wales, Randwick, Australia; 8Insti tute of Liver Studies, Kings College Hospital NHS Foundation Trust, London, United Kingdom
|
| |
|
|
|
|
|
